Ionis Pharmaceuticals
IONS
361 hedge funds and large institutions have $6.17B invested in Ionis Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 123 increasing their positions, 128 reducing their positions, and 50 closing their positions.
75% more call options, than puts
Call options by funds: $48.1M | Put options by funds: $27.5M
0% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 50
1% less funds holding
Funds holding: 363 → 361 (-2)
4% less repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 128
2.56% less ownership
Funds ownership: 100.12% → 97.56% (-2.6%)
15% less capital invested
Capital invested by funds: $7.27B → $6.17B (-$1.1B)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$51.4M |
| 2 |
BlackRock
New York
|
+$34.1M |
| 3 |
Squarepoint
New York
|
+$32.7M |
| 4 |
BNP Paribas Asset Management
Paris,
France
|
+$20.9M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$19.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$48.5M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$43.9M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$43.8M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$39.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$36.8M |
IONS Hedge Fund Activity: Q1 2024 in Review
361 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q1 2024, worth a combined $6.17B — down 15% from $7.27B a quarter earlier.
Fund positioning in IONS was balanced in Q1 2024: 50 funds opened new positions, 50 closed out, 123 added to existing stakes and 128 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $51.4M. The largest seller was Morgan Stanley, cutting an estimated $48.5M.
- 361 institutional investors held Ionis Pharmaceuticals (IONS) as of Q1 2024, down from 363 in Q4 2023.
- Funds reported $6.17B of Ionis Pharmaceuticals stock for Q1 2024, down 15% quarter-over-quarter.
- 50 funds opened new Ionis Pharmaceuticals positions in Q1 2024 and 50 closed out, a net change of 0 holders.
- The largest Ionis Pharmaceuticals buyer in Q1 2024 was Wellington Management Group, an estimated $51.4M added.
- The largest Ionis Pharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $48.5M sold.
Based on aggregated 13F filings for Q1 2024.